- Home
- CGEN vs GRX Comparison
CGEN vs GRX Comparison
Compare CGEN & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- GRX
- Stock Information
- Founded
- CGEN 1993
- GRX 2007
- Country
- CGEN Israel
- GRX United States
- Employees
- CGEN N/A
- GRX N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- GRX Finance/Investors Services
- Sector
- CGEN Health Care
- GRX Finance
- Exchange
- CGEN Nasdaq
- GRX Nasdaq
- Market Cap
- CGEN 142.8M
- GRX 165.9M
- IPO Year
- CGEN 2000
- GRX N/A
- Fundamental
- Price
- CGEN $1.60
- GRX $9.93
- Analyst Decision
- CGEN Strong Buy
- GRX
- Analyst Count
- CGEN 2
- GRX 0
- Target Price
- CGEN $4.00
- GRX N/A
- AVG Volume (30 Days)
- CGEN 445.1K
- GRX 39.7K
- Earning Date
- CGEN 11-12-2024
- GRX 01-01-0001
- Dividend Yield
- CGEN N/A
- GRX 5.98%
- EPS Growth
- CGEN N/A
- GRX N/A
- EPS
- CGEN 0.02
- GRX 0.26
- Revenue
- CGEN $59,852,000.00
- GRX N/A
- Revenue This Year
- CGEN $57.27
- GRX N/A
- Revenue Next Year
- CGEN N/A
- GRX N/A
- P/E Ratio
- CGEN $88.75
- GRX $38.50
- Revenue Growth
- CGEN 698.03
- GRX N/A
- 52 Week Low
- CGEN $1.35
- GRX $7.73
- 52 Week High
- CGEN $3.03
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- CGEN 51.01
- GRX 38.86
- Support Level
- CGEN $1.55
- GRX $9.76
- Resistance Level
- CGEN $1.68
- GRX $10.46
- Average True Range (ATR)
- CGEN 0.08
- GRX 0.12
- MACD
- CGEN 0.01
- GRX -0.04
- Stochastic Oscillator
- CGEN 52.17
- GRX 30.26
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.